Currently, there are 47.04M common shares owned by the public and among those 43.71M shares have been available to trade.
The company’s stock has a 5-day price change of 4.46% and 32.14% over the past three months. UTHR shares are trading 65.33% year to date (YTD), with the 12-month market performance up to 59.14% higher. It has a 12-month low price of $208.62 and touched a high of $365.98 over the same period. UTHR has an average intraday trading volume of 551.04K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.84%, 10.37%, and 38.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of United Therapeutics Corp (NASDAQ: UTHR) shares accounts for 104.75% of the company’s 47.04M shares outstanding.
It has a market capitalization of $16.17B and a beta (3y monthly) value of 0.56. The stock’s trailing 12-month PE ratio is 16.70, while the earnings-per-share (ttm) stands at $21.77. The company has a PEG of 0.95 and a Quick Ratio of 4.18 with the debt-to-equity ratio at 0.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.33% over the week and 2.86% over the month.
Earnings per share for the fiscal year are expected to increase by 24.16%, and 14.82% over the next financial year. EPS should grow at an annualized rate of 17.60% over the next five years, compared to 8.15% over the past 5-year period.
Looking at the support for the UTHR, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on July 11, 2024, with the firm’s price target at $310-$321. Goldman coverage for the United Therapeutics Corp (UTHR) stock in a research note released on February 12, 2024 offered a Neutral rating with a price target of $215. Leerink Partners was of a view on February 05, 2024 that the stock is Outperform, while Wells Fargo gave the stock Overweight rating on December 08, 2023, issuing a price target of $309. UBS on their part issued Buy rating on December 06, 2022.
